✦ LIBER ✦

102 EFFECTS OF SATAVAPTAN, AN ORAL VASOPRESSIN V2 RECEPTOR ANTAGONIST, ON MANAGEMENT OF ASCITES AND MORBIDITY IN LIVER CIRRHOSIS IN A LONG-TERM, PLACEBO-CONTROLLED STUDY

✍ Scribed by F. Wong; M. Bernardi; Y. Horsmans; Z. Cabrijan; H. Watson; P. Gines

Book ID: 117377113
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 66 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60104-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trial: short-term effects of co

Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double-blind, placebo-controlled study

✍ P. GINÈS; F. WONG; H. WATSON; R. TERG; R. BRUHA; J.-P. ZARSKI; F. DUDLEY; FOR TH 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses

732 Effects of satavaptan (SR121463B), a

732 Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia

✍ P. Gines; F. Wong; S. Milutinovic; L. Ruiz del Arbol; D. Olteanu 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB